- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7233
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Galectin-3: an immune checkpoint target for musculoskeletal tumor patients ; day:14 ; month:9 ; year:2020 ; pages:1-6
Cancer and metastasis reviews ; (14.9.2020), 1-6
- Creator
-
Nakajima, Kosei
Balan, Vitaly
Raz, Avraham
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10555-020-09932-4
- URN
-
urn:nbn:de:101:1-2020110222263110515591
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Nakajima, Kosei
- Balan, Vitaly
- Raz, Avraham
- SpringerLink (Online service)
Other Objects (12)
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target
GPCRs: emerging targets for novel T cell immune checkpoint therapy
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy
Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer
TrkB-target Galectin-1 impairs immune activation and radiation responses in neuroblastoma: implications for tumour therapy
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
Neurosarcoidosis following Immune Checkpoint Inhibition
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
Immune checkpoint gene signature assesses immune infiltration profiles in bladder cancer and identifies KRT23 as an immunotherapeutic target
ZDHHC9: a promising therapeutic target for triple-negative breast cancer through immune modulation and immune checkpoint blockade resistance
Advances in molecular imaging of immune checkpoint targets in malignancies: current and future prospect
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target
GPCRs: emerging targets for novel T cell immune checkpoint therapy
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy
Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer
TrkB-target Galectin-1 impairs immune activation and radiation responses in neuroblastoma: implications for tumour therapy
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
Neurosarcoidosis following Immune Checkpoint Inhibition
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
Immune checkpoint gene signature assesses immune infiltration profiles in bladder cancer and identifies KRT23 as an immunotherapeutic target
ZDHHC9: a promising therapeutic target for triple-negative breast cancer through immune modulation and immune checkpoint blockade resistance
Advances in molecular imaging of immune checkpoint targets in malignancies: current and future prospect
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target
GPCRs: emerging targets for novel T cell immune checkpoint therapy
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy
Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer
TrkB-target Galectin-1 impairs immune activation and radiation responses in neuroblastoma: implications for tumour therapy
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
Neurosarcoidosis following Immune Checkpoint Inhibition
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
Immune checkpoint gene signature assesses immune infiltration profiles in bladder cancer and identifies KRT23 as an immunotherapeutic target
ZDHHC9: a promising therapeutic target for triple-negative breast cancer through immune modulation and immune checkpoint blockade resistance